BSX · Boston Scientific Corp
United States · RS rating 23 · As of 2026-10-14
| Price | 43.00 USD |
|---|---|
| 1-day change | -0.7% |
| RS rating (overall / 1M / 3M / 12M) | 23 / 52 / 48 / 12 |
| Stage | Declining |
| Composite / Minervini / CANSLIM score | 24 / 8 / 23 |
| Industry group (rank) | Medical-Products (98) |
| EPS growth Q/Q | -11.8% |
| Sales growth Q/Q | +4.4% |
| Distance from 52-week high | +59.0% |
| Market cap (USD) | $97.6B |